Drugs / SHR-1603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03722186 | Nov 2018 → Apr 2019 | lymphoma | Jiangsu HengRui Medicine Co., Ltd. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03722186 ↗ |
| Route | Intravenous | “The study drug will be administered by intravenous infusion.” NCT03722186 ↗ |